nigrostriatal

(redirected from Nigrostriatal pathway)
Also found in: Wikipedia.

nigrostriatal

 [ni″gro-stri-a´tal]
projecting from the substantia nigra to the corpus striatum; said of a bundle of nerve fibers.

ni·gro·stri·a·tal

(nī'grō-strī-ā'tăl),
Referring to the efferent connection of the substantia nigra (especially its compact part) with the striatum. See: substantia nigra.

ni·gro·stri·a·tal

(nī'grō-strī-ā'tăl)
Referring to the efferent connection of the substantia nigra with the striatum.
See: substantia nigra
References in periodicals archive ?
The most common PD treatment today is based on enhancing the activity of the nigrostriatal pathway in the brain with dopamine-modulating therapies, thereby increasing striatal dopamine levels and improving motor impairment associated with the disease.
Motor planning and movement are the primary functions of nigrostriatal pathway. Tuberinfundibular pathway regulates the secretion of Prolactin from anterior Pituitary gland (Stahl, 2002).
Prickaerts, "Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway," Experimental Neurology, vol.
This hallmark of manganese-induced parkinsonism correlates with the nigrostriatal pathway preservation.
Whether these inflammatory processes are directly involved in the etiology of PD or represent secondary consequences of nigrostriatal pathway injury is the subject of intensive research.
It is suggested that the ability to create NMS by neuroleptics is associated with their ability to block dopamine in the nigrostriatal pathway, mesocortical pathway, and hypothalamic nucleus.
Paraquat exposure affects the nigrostriatal pathway, producing alterations in dopaminergic markers [24, 33, 34].
Degeneration of dopamine-producing neurons in striatum complex leads to diminished concentrations of dopamine in the nigrostriatal pathway, leading to reduce function and the characteristic symptoms, such as motor ability and cognitive impairment [23-25].
The intrastriatal injection of 6-OHDA causes a progressive retrograde and dose-dependent neuronal degeneration in the nigrostriatal pathway [13, 14].
Degeneration of the nigrostriatal pathway causes striatal dopamine deficiency, which leads to symptoms of PD.